Related Experiment Videos
Parathyroid hormone: what are we measuring and does it matter?
Aubrey Blumsohn1, Amna Al Hadari
1Division of Clinical Sciences (North), University of Sheffield, Northern General Hospital, UK. ablumsohn@sheffield.ac.uk
Annals of Clinical Biochemistry
|June 1, 2002
Summary
New parathyroid hormone (PTH) assays may offer benefits for chronic renal failure patients. However, current intact PTH assays remain effective for most common conditions like primary hyperparathyroidism.
Area of Science:
- Endocrinology
- Clinical Chemistry
- Assay Development
Background:
- Intact parathyroid hormone (PTH) assays often cross-react with N-truncated PTH fragments, such as PTH(7-84).
- The clinical relevance of specific PTH assays, particularly PTH(1-84), requires careful evaluation.
Purpose of the Study:
- To assess the clinical utility of new PTH assays with claimed PTH(1-84) specificity.
- To compare the performance and interpretation of new PTH assays against existing intact PTH assays.
Main Methods:
- Review of existing literature on PTH assay cross-reactivity and clinical applications.
- Analysis of potential impact of PTH(1-84) specific assays on patient outcomes in various conditions.
Main Results:
- Existing intact PTH assays are generally sufficient for interpreting results in primary hyperparathyroidism and vitamin D deficiency.
- New PTH(1-84) assays show potential for improving outcomes in chronic renal failure, but straightforward replacement is not yet supported.
- Understanding PTH fragments and receptor interactions is key to assay relevance.
Conclusions:
- While new PTH(1-84) assays hold promise, especially for chronic kidney disease, current intact PTH assays remain reliable for most clinical scenarios.
- Further research into PTH fragments and receptor binding is needed to fully elucidate the benefits of specific PTH assays.